Yes, THC (tetrahydrocannabinol) is a Schedule I controlled substance under federal law in the United States. The Controlled Substances Act places it in the most restrictive category, alongside heroin, LSD, and psilocybin. That said, the legal picture is more complicated than a single classification suggests. The specific form of THC, where it comes from, and what state you’re in all affect whether it’s treated as illegal, regulated, or freely sold.
Federal Classification Under the CSA
The Code of Federal Regulations lists tetrahydrocannabinols under Schedule I, section 1308.11, categorized as a hallucinogenic substance. Schedule I is reserved for substances the federal government considers to have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. No prescriptions can be written for Schedule I substances.
The federal definition is broad. It covers THC naturally found in cannabis plants, synthetic equivalents, and any derivatives or isomers with a similar chemical structure and pharmacological activity. This means the law doesn’t just target delta-9 THC (the compound most people mean when they say “THC”). It technically encompasses multiple forms of the molecule, regardless of how they’re named or numbered in different chemical naming systems.
There is one critical carve-out: THC does not include any material that qualifies as hemp under federal law. That distinction is where things get interesting.
The Hemp Exception: 0.3% THC
The 2018 Farm Bill created a legal boundary based on THC concentration. Cannabis containing 0.3% or less delta-9 THC on a dry weight basis is classified as hemp and is not a controlled substance. Cannabis above that threshold remains a controlled substance that must be disposed of according to USDA-approved methods.
This 0.3% line is why you can buy CBD products, certain hemp-derived edibles, and other cannabinoid products in many stores without a prescription or a dispensary license. As long as the delta-9 THC content stays at or below that threshold, the product falls outside the Controlled Substances Act entirely.
Delta-8 THC and Other Isomers
The hemp exception created a gray area that manufacturers have exploited. Delta-8 THC, a less potent cousin of delta-9, can be chemically converted from CBD extracted from legal hemp. Because the 2018 Farm Bill’s THC limit specifically references delta-9, some companies have argued that delta-8 products derived from hemp are federally legal.
The DEA disagrees. The agency has stated that it considers delta-8 THC an analog of delta-9 THC, which would place it under similar regulatory restrictions. A proposed revision to the Farm Bill would close this loophole by imposing limits on “total THC” (including delta-8) and restricting the sale of cannabinoid products made through chemical conversion processes like isomerization. At the time of writing, final rules have not been established, leaving delta-8 in legal limbo at the federal level. Several states have moved ahead with their own bans or restrictions.
FDA-Approved THC Medications Have Lower Schedules
While THC itself sits in Schedule I, certain FDA-approved medications containing synthetic THC have been rescheduled into less restrictive categories. This is one of the more confusing aspects of federal drug law: the same molecule can be in different schedules depending on the product it’s in.
- Dronabinol capsules (Marinol) contain synthetic delta-9 THC in sesame oil, encapsulated in a soft gelatin capsule. This formulation is Schedule III, meaning doctors can prescribe it. It’s used for nausea from chemotherapy and appetite loss in AIDS patients.
- Dronabinol oral solution (Syndros) contains the same active ingredient in liquid form but is classified as Schedule II, reflecting the agency’s view that the liquid form carries different abuse potential.
- Nabilone (Cesamet) is a synthetic compound with a chemical structure similar to THC, also rescheduled to Schedule II after FDA approval.
None of these products could be marketed immediately after FDA approval. They had to go through a separate DEA rescheduling process first, because the active ingredients were still considered Schedule I substances in their raw form. The practical result: a doctor can prescribe you a capsule of synthetic THC, but possessing plant-derived THC remains a federal offense.
State Laws Create a Patchwork
The federal Schedule I classification exists alongside a growing number of state laws that legalize or decriminalize marijuana. As of now, the majority of U.S. states have legalized cannabis in some form, whether for medical use, recreational use, or both. In those states, THC is either removed from the state’s own controlled substance list or exempted for qualifying individuals.
This creates a genuine legal conflict. A person using THC legally under state law is still technically violating federal law. In practice, the federal government has largely declined to prosecute individuals complying with state cannabis programs, but the Schedule I status carries real consequences. It affects banking access for cannabis businesses, limits research, prevents standard insurance coverage, and can create problems for federal employees, military personnel, and anyone subject to federal drug testing.
A reclassification petition for marijuana was denied in 2001 despite growing state-level legalization. The conflict between state and federal law has only widened since then.
Rescheduling Efforts Are Underway
The federal government is actively considering moving marijuana, and by extension THC, from Schedule I to Schedule III. In 2023, the Department of Health and Human Services recommended the change, and the National Institute on Drug Abuse concurred. In May 2024, the Department of Justice issued a formal proposed rule to reschedule marijuana to Schedule III.
That proposed rule received nearly 43,000 public comments and is currently awaiting an administrative law hearing. A White House directive has instructed the Attorney General to complete the rescheduling process “in the most expeditious manner” allowed by federal law.
If marijuana moves to Schedule III, THC would no longer be treated as having “no accepted medical use.” Doctors could prescribe it more broadly, cannabis businesses could take standard tax deductions, and research barriers would drop significantly. It would not make recreational marijuana federally legal. Schedule III substances, like anabolic steroids and certain codeine formulations, are still controlled and regulated. Possession without a prescription would remain a federal offense.
International Classification
The United States isn’t acting in isolation. Cannabis has been regulated internationally since 1925, when it was included in the League of Nations’ Geneva Opium Convention. The United Nations Single Convention on Narcotic Drugs of 1961 placed cannabis in both Schedule I (high addiction potential and abuse liability) and Schedule IV (the most restrictive tier, reserved for substances considered to lack therapeutic value).
That changed in December 2020, when the UN Commission on Narcotic Drugs adopted a World Health Organization recommendation and removed cannabis from Schedule IV. The WHO had concluded that the Schedule IV placement ignored the plant’s therapeutic value. Cannabis remains in UN Schedule I, but its removal from the harshest category provides a framework that many countries are now using to revisit their own domestic cannabis laws.